Home/Pipeline/Ropidoxuridine (IPdR)

Ropidoxuridine (IPdR)

Glioblastoma

Phase 2Active

Key Facts

Indication

Glioblastoma

Phase

Phase 2

Status

Active

Company

Shuttle Pharmaceuticals

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals is a clinical-stage biotech focused on enhancing radiation therapy (RT) for cancer through novel small molecule therapies. Its mission is to increase cure rates and improve quality of life by developing targeted radiation sensitizers and protective agents. The company's strategy leverages a dual-platform approach of halogenated pyrimidines and selective HDAC inhibitors, with a lead Phase II candidate, Ropidoxuridine, in glioblastoma. Shuttle is advancing its pipeline through strategic academic collaborations and recently announced initiatives in AI for scientific workflows.

View full company profile

Therapeutic Areas

Oncology Radiation Oncology

Other Glioblastoma Drugs

Drug	Company	Phase	Status
LNTH-2505	Lantheus Medical Imaging	Preclinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
Glioblastoma Moonshot	Owkin	Research	Open Project
OPC-001 (PDC Candidate)	Oncopeptides	Phase 1/Window-of-Opportunity	Active (Fast-Track Designation)
αvβ3-targeted ADC	Xintela	Preclinical	Lead Optimization
GLIX1	Hemispherian	Phase 1	Active
InC01	InCephalo Therapeutics	Pre-clinical	Active
Glioblastoma Combination Therapy	JLP Health	Pre-clinical	Active
ENV105	Kairos Pharma	IND Cleared	Active
LMP744	Gibson Oncology	Phase 2	Active
BEA-17	Beactica Therapeutics	Pre-clinical	Active
SFK Inhibitor	Lead Discovery Siena	Preclinical	Active